Release kinetics of N-terminal pro-B-type natriuretic peptide in a clinical model of acute myocardial infarction

Clinica Chimica Acta

Volumn 429, Issue , 2014, Pages 34-37

  Liebetrau, Christoph ^a,b,c   Gaede, Luise ^a,b   Dörr, Oliver ^b   Troidl, Christian ^a,b   Voss, Sandra ^a,b   Hoffmann, Jedrzej ^a,b   Paszko, Agata ^a,b   Weber, Michael ^a,b   Rolf, Andreas ^a,b   Hamm, Christian ^a,b,c   Nef, Holger ^b   Möllmann, Helge ^a,b  

^a Kerckhoff Heart and Thorax Center   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

N terminal pro B type natriuretic peptide; Release kinetics; Transcoronary ablation of septal hypertrophy

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ABLATION THERAPY; ACUTE HEART INFARCTION; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; FEMALE; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; TRANSCORONARY ABLATION OF SEPTAL HYPERTROPHY;

EID: 84889654274     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.11.017     Document Type: Article

References (28)

1. Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N Engl J Med 1998, 339:321-328.
2. Möllmann H., Nef H.M., Kostin S., et al. Ischemia triggers BNP expression in the human myocardium independent from mechanical stress. Int J Cardiol 2010, 143:289-297.
3. Morita E., Yasue H., Yoshimura M., et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993, 88:82-91.
4. Clerico A., Giannoni A., Vittorini S., et al. Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol 2011, 301:H12-H20.
5. Nieminen M.S., Böhm M., Cowie M.R., et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005, 26:384-416.
6. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005, 26:1115-1140.
7. Masson S., Latini R., Anand I.S., et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006, 52:1528-1538.
8. Clerico A., Fontana M., Zyw L., et al. Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure. A systematic review. Clin Chem 2007, 53:813-822.
9. Ang D.S., Kong C.F., Kao M.P., Struthers A.D. Serial bedside B-type natriuretic peptide strongly predicts prognosis in acute coronary syndrome independent of echocardiographic abnormalities. Am Heart J 2009, 158:13-40.
10. Scirica B.M., Sabatine M.S., Jarolim P., et al. Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. Eur Heart J 2011, 32:697-705.
11. Eggers K.M., Lagerqvist B., Venge P., et al. Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol 2009, 54:356-364.
12. Haeck J.D., Verouden N.J., Kuijt W.J., et al. Comparison of usefulness of N-terminal pro-brain natriuretic peptide as an independent predictor of cardiac function among admission cardiac serum biomarkers in patients with anterior wall versus nonanterior wall ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2010, 105:1065-1069.
13. Seo S.M., Kim S., Chang K., et al. Plasma B-type natriuretic peptide level can predict myocardial tissue perfusion in patients undergoing primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Coron Artery Dis 2011, 22:405-410.
14. Lindahl B., Lindbäck J., Jernberg T., et al. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol 2005, 45:533-541.
15. Heeschen C., Hamm C.W., Mitrovic V., et al. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004, 110:3206-3212.
16. Weber M., Kleine C., Keil E., et al. Release pattern of N-terminal pro B-type natriuretic peptide (NT-proBNP) in acute coronary syndromes. Clin Res Cardiol 2006, 95:270-280.
17. Liebetrau C., Moellmann H., Nef H., et al. Release kinetics of cardiac biomarkers in patients undergoing transcoronary ablation of septal hypertrophy. Clin Chem 2012, 58:1049-1054.
18. Liebetrau C., Nef H., Szardien S., et al. Release kinetics of copeptin in patients undergoing transcoronary ablation of septal hypertrophy. Clin Chem 2013, 59:566-569.
19. Liebetrau C., Möllmann H., Dörr O., et al. Release kinetics of circulating muscle-enriched microRNAs in patients undergoing transcoronary ablation of septal hypertrophy. J Am Coll Cardiol 2013, 62:992-998.
20. Maron B.J., McKenna W.J., Danielson G.K., et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003, 42:1687-1713.
21. Omland T., Persson A., NG L., et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002, 106:2913-2918.
22. Weber M., Bazzino O., Navarro Estrada J.L., et al. N-terminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndrome and normal troponin T values upon admission. J Am Coll Cardiol 2008, 51:1188-1195.
23. Szardien S., Hef H.M., Möllmann H., et al. Transient elevation of NT-proBNP as a predictor for myocardial ischemia. Clin Res Cardiol 2010, 99:857-859.
24. D'Amato R., Tomberli B., Castelli G., et al. Prognostic value of N-terminal pro-brain natriuretic peptide in outpatients with hypertrophic cardiomyopathy. Am J Cardiol 2013, 112:1190-1196.
25. Park J.R., Choi J.O., Han H.J., et al. Degree and distribution of left ventricular hypertrophy as a determining factor for elevated natriuretic peptide levels in patients with hypertrophic cardiomyopathy: insights from cardiac magnetic resonance imaging. Int J Cardiovasc Imaging 2012, 28:763-772.
26. Weber M., Arnold R., Rau M., et al. Relation of N-terminal pro B-Type natriuretic peptide to progression of aortic valve disease. Eur Heart J 2005, 26:1023-1030.
27. Basic D., Möllmann H., Haas M.A., et al. A TASH experience: post-infarction myocardial oedema necessitating the support of ECMO and occurrence of significant mitral regurgitation. Clin Res Cardiol 2012, 101:149-153.
28. Omland T., Pfeffer M.A., Solomon S.D., et al. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol 2013, 61:1240-1249.